|
1.
|
|
11 p, 21.0 MB |
Analysis of Tumor Microenvironment Changes after Neoadjuvant Chemotherapy with or without Bevacizumab in Advanced Ovarian Cancer (GEICO-89T/MINOVA Study)
/
Tavira, Beatriz (Cancer Center Clínica Universidad de Navarra) ;
Iscar, Teresa (Cancer Center Clínica Universidad de Navarra) ;
Manso, Luis (Hospital 12 de Octubre (Madrid)) ;
Santaballa, Ana (Hospital Universitari i Politècnic La Fe (València)) ;
Gil-Martin, Marta (Institut Català d'Oncologia - Hospital Duran i Reynals) ;
García García, Yolanda (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ;
Romeo, Margarita (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Iglesias, Maria (Hospital Son Llátzer) ;
de Juan Ferre, Ana (Hospital Marqués de Valdecilla) ;
Barretina-Ginesta, Maria-Pilar (Institut Català d'Oncologia) ;
Manzano, Aranzazu (Hospital Clínico San Carlos (Madrid)) ;
Gaba, Lydia (Hospital Clínic i Provincial de Barcelona) ;
Rubio, Maria Jesus (Hospital Universitario Reina Sofía (Córdoba, Espanya)) ;
de Andrea, Carlos E. (Centro de Investigación Biomédica en Red de Cáncer) ;
González-Martín, Antonio (Cancer Center Clínica Universidad de Navarra) ;
Universitat Autònoma de Barcelona
The aim of our study was to elucidate the impact of bevacizumab added to neoadjuvant chemotherapy (NACT) on the tumor immune microenvironment and correlate the changes with the clinical outcome of the patients. [...]
2023 -  10.1158/1078-0432.CCR-23-0771
Clinical Cancer Research, Vol. 30 (august 2023) , p. 176-186
|
|
|
2.
|
|
9 p, 442.2 KB |
B-cell Receptor Pathway Mutations Are Infrequent in Patients with Chronic Lymphocytic Leukemia on Continuous Ibrutinib Therapy
/
Woyach, Jennifer A. (The Ohio State University Comprehensive Cancer Center, Columbus, Ohio) ;
Ghia, Paolo (Universita Vita-Salute San Raffaele, Milan, Italy) ;
Byrd, John C. (University of Cincinnati College of Medicine, Cincinnati, Ohio) ;
Ahn, Inhye E. (Laboratory of Lymphoid Malignancies, National Heart, Lung, and Blood Institute, NIH, Bethesda, Maryland) ;
Moreno, Carol (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Brien, Susan M. (UC Irvine. Chao Family Comprehensive Cancer Center, Irvine, California) ;
Jones, Daniel (The Ohio State University Comprehensive Cancer Center, Irvine, California) ;
Cheung, Leo W.K. (Pharmacyclics LLC, an AbbVie Company, South San Francisco, California) ;
Chong, Elizabeth (Pharmacyclics LLC, an AbbVie Company, South San Francisco, California) ;
Kwei, Kevin (Pharmacyclics LLC, an AbbVie Company, South San Francisco, California) ;
Dean, James P. (Pharmacyclics LLC, an AbbVie Company, South San Francisco, California) ;
James, Dannelle F. (Pharmacyclics LLC, an AbbVie Company, South San Francisco, California) ;
Wiestner, Adrian (Laboratory of Lymphoid Malignancies, National Heart, Lung, and Blood Institute, NIH, Bethesda, Maryland)
Purpose: Acquired mutations in Bruton's tyrosine kinase (BTK) or phospholipase C-γ2 (PLCG2) genes are associated with clinical progressive disease (PD) in patients with chronic lymphocytic leukemia (CLL) treated with BTK inhibitors. [...]
2023 - 10.1158/1078-0432.CCR-22-3887
Clinical Cancer Research, Vol. 29 Núm. 16 (august 2023) , p. 3065-3073
|
|
|
3.
|
|
11 p, 421.8 KB |
Health-Related Quality of Life Outcomes in Patients with Resected Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer Who Received Adjuvant Osimertinib in the Phase III ADAURA Trial
/
Majem, Margarita (Institut d'Investigació Biomèdica Sant Pau) ;
Goldman, Jonathan W. (David Geffen School of Medicine. University of California Los Angeles) ;
John, Thomas (Department of Medical Oncology. Austin Health) ;
Grohe, Christian (Klinik fur € Pneumologie-Evangelische Lungenklinik Berlin Buch) ;
Laktionov, Konstantin (N.N. Blokhin National Medical Research Center of Oncology (Rússia)) ;
Kim, Sang-We (Department of Oncology. Asan Medical Center) ;
Kato, Terufumi (Depart-ment of Thoracic Oncology. Kanagawa Cancer Center) ;
Vu, Huu Vinh (Department of Thoracic Surgery. Choray Hospital) ;
Lu, Shun (Lung Cancer Center. Shanghai Chest Hospital. Shanghai Jiao Tong University) ;
Li, Shanqing (Department of Thoracic Surgery. Peking Union Medical College Hospital. Chinese Academy of Medical Sciences) ;
Lee, Kye Young (Pre-cision Medicine Lung Cancer Center. Konkuk University Medical Center) ;
Akewanlop, Charuwan (Division of Medical Oncology. Faculty of Medicine. Siriraj Hospital) ;
Yu, Chong-Jen (Department of Internal Medicine. National Taiwan University Hospital Hsinchu Branch. National Taiwan University College of Medicine) ;
De Marinis, Filippo (Thoracic Oncology Division. European Institute of Oncology (IEO). IRCCS) ;
Bonanno, Laura (Medical Oncology 2. Istituto Oncologico Veneto (IOV). IRCCS) ;
Domine, Manuel (Hospital Universitario Fundacion Jimenez Díaz. Servicio de Oncología) ;
Shepherd, Frances A. (Department of Medical Oncology and Hematology. University Health Network. Princess Margaret Cancer Center. the University of Toronto) ;
Atagi, Shinji (Department of Thoracic Oncology. National Hospital Organization Kinki-Chuo Chest Medical Center) ;
Zeng, Lingmin (Late Oncology Statistics. AstraZeneca) ;
Kulkarni, Dakshayini (Late Oncology R&D. AstraZeneca) ;
Medic, Nenad (AstraZeneca Oncology Business Unit. Academy House) ;
Tsuboi, Masahiro (Department of Thoracic Surgery and Oncology. National Cancer Center Hospital East) ;
Herbst, Roy S. (Medical Oncology. Yale School of Medicine. Yale Cancer Center) ;
Wu, Yi-Long (Guangdong Lung Cancer Institute)
Purpose: In the phase III ADAURA trial, adjuvant treatment with osimertinib versus placebo, with/without prior adjuvant chemotherapy, resulted in a statistically significant and clinically meaningful disease-free survival benefit in completely resected stage IB-IIIA EGFR-mutated (EGFRm) non-small cell lung cancer (NSCLC). [...]
2022 - 10.1158/1078-0432.CCR-21-3530
Clinical Cancer Research, Vol. 28 Núm. 11 (january 2022) , p. 2286-2296
|
|
|
4.
|
|
12 p, 506.4 KB |
Results from a First-in-Human Phase I Study of Siremadlin (HDM201) in Patients with Advanced Wild-Type TP53 Solid Tumors and Acute Leukemia
/
Stein, Eytan M. (Memorial Sloan Kettering Cancer Center (New York)) ;
DeAngelo, Daniel J. (Dana-Farber Cancer Institute (Boston, Massachusetts)) ;
Chromik, Jörg (Goethe University Frankfurt) ;
Chatterjee, Manik (University Hospital of Würzburg) ;
Bauer, Sebastian (German Consortium of Translational Cancer Research (DKTK)) ;
Lin, Chia-Chi (National Taiwan University Hospital (Taipei, Taiwan)) ;
Suárez, Cristina (Vall d'Hebron Institut d'Oncologia) ;
de Vos, Filip (University Medical Center Utrecht) ;
Steeghs, Neeltje (The Netherlands Cancer Institute (Amsterdam, Països Baixos)) ;
Cassier, Philippe A. (Léon Bérard Center) ;
Tai, David (National Cancer Center Singapore) ;
Kiladjian, Jean-Jacques (Université de Paris) ;
Yamamoto, Noboru (National Cancer Center Hospital (Tokyo, Japó)) ;
Mous, Rogier (University Medical Center Utrecht) ;
Esteve Reyner, Jordi (Hospital Clínic i Provincial de Barcelona) ;
Minami, Hironobu (Kobe University Graduate School of Medicine and Hospital (Japó)) ;
Ferretti, Stephane (Novartis Institutes for Biomedical Research) ;
Guerreiro, Nelson (Novartis Institutes for Biomedical Research) ;
Meille, Christophe (Novartis Institutes for Biomedical Research) ;
Radhakrishnan, Rajkumar (Novartis Healthcare Private Limited (Hyderabad, India)) ;
Pereira, Bernard (Novartis Institutes for BioMedical Research (Cambridge, Massachusetts)) ;
Mariconti, Luisa (Novartis Institutes for Biomedical Research) ;
Halilovic, Ensar (Novartis Institutes for BioMedical Research (Cambridge, Massachusetts)) ;
Fabre, Claire (Novartis Institutes for Biomedical Research) ;
Carpio Segura, Cecilia del Carmen (Vall d'Hebron Institut d'Oncologia) ;
Universitat Autònoma de Barcelona
This phase I, dose-escalation study investigated the recommended dose for expansion (RDE) of siremadlin, a p53-MDM2 inhibitor, in patients with wild-type TP53 advanced solid or hematologic cancers. Initial dosing regimens were: 1A (day 1; 21-day cycle; dose 12. [...]
2021 - 10.1158/1078-0432.CCR-21-1295
Clinical Cancer Research, Vol. 28 (december 2021) , p. 870-881
|
|
|
5.
|
|
11 p, 1.4 MB |
Antitumor Activity of the Novel BTK Inhibitor TG-1701 Is Associated with Disruption of Ikaros Signaling in Patients with B-cell Non-Hodgkin Lymphoma
/
Ribeiro, Marcelo Lima (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Reyes, Diana (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Vinyoles, Meritxell (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Profitós-Pelejà, Núria (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Santos, Juliana (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Armengol, Marc Antoni (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Fernández-Serrano, Miranda (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Sedó Mor, Alícia (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Bech-Serra, Joan-Josep (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Blecua, Pedro (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Musulén, Eva (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
De La Torre Gómez, Gisela Carolina (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Miskin, Hari (TG Therapeutics (Nova York)) ;
Esteller, M. (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Bosch José, Francesc Xavier 1947- (Vall d'Hebron Institut d'Oncologia) ;
Menéndez Bujan, Pablo (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Normant, Emmanuel (TG Therapeutics (Nova York)) ;
Roué, Gaël (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Universitat Autònoma de Barcelona
Despite the remarkable activity of BTK inhibitors (BTKi) in relapsed B-cell non-Hodgkin lymphoma (B-NHL), no clinically-relevant biomarker has been associated to these agents so far. The relevance of phosphoproteomic profiling for the early identification of BTKi responders remains underexplored. [...]
2021 - 10.1158/1078-0432.CCR-21-1067
Clinical Cancer Research, Vol. 27 (september 2021) , p. 6591-6601
|
|
|
6.
|
|
13 p, 941.6 KB |
Pretreatment tissue TCR repertoire evenness is associated with complete pathologic response in patients with NSCLC receiving neoadjuvant chemoimmunotherapy
/
Casarrubios, Marta (Instituto de Investigación Sanitaria Puerta de Hierro - Segovia de Arana) ;
Cruz-Bermúdez, Alberto (Instituto de Investigación Sanitaria Puerta de Hierro - Segovia de Arana) ;
Nadal, Ernest (Institut Català d'Oncologia) ;
Insa, Amelia (Hospital Clínic Universitari (València)) ;
García Campelo, María del Rosario (Complejo Hospitalario Universitario de A Coruña) ;
Lázaro, Martín (Hospital Universitario de Vigo) ;
Dómine Gómez, Manuel (Hospital Universitario Fundación Jiménez Díaz) ;
Majem, Margarita (Institut d'Investigació Biomèdica Sant Pau) ;
Rodríguez-Abreu, Delvys (Hospital Universitario Insular de Gran Canaria) ;
Martinez-Marti, Alex (Vall d'Hebron Institut d'Oncologia) ;
de Castro, Javier (Hospital Universitario La Paz (Madrid)) ;
Cobo, Manuel (Hospital Regional Universitario de Málaga) ;
López-Vivanco, Guillermo (Hospital Universitario de Cruces (Barakaldo, País Basc)) ;
Del Barco Morillo, Edel (Hospital Universitario de Salamanca) ;
Bernabé, Reyes (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ;
Viñolas, Nuria (Hospital Clínic i Provincial de Barcelona) ;
Barneto Aranda, Isidoro (Hospital Universitario Reina Sofía (Còrdova, Espanya)) ;
Viteri, Santiago (Instituto Oncológico Dr. Rosell. Hospital Universitario Quiron Dexeus) ;
Massuti, Bartomeu (Hospital General Universitario de Alicante (Alacant, País Valencià)) ;
Barquín, Miguel (Instituto de Investigación Sanitaria Puerta de Hierro - Segovia de Arana) ;
Laza-Briviesca, Raquel (Instituto de Investigación Sanitaria Puerta de Hierro - Segovia de Arana) ;
Sierra-Rodero, Belén (Instituto de Investigación Sanitaria Puerta de Hierro - Segovia de Arana) ;
Parra, Edwin R. (The University of Texas. Department of Translational Molecular Pathology) ;
Sanchez-Espiridion, Beatriz (The University of Texas. Department of Translational Molecular Pathology) ;
Rocha, Pedro (The University of Texas. Department of Translational Molecular Pathology) ;
Kadara, Humam (The University of Texas. Department of Translational Molecular Pathology) ;
Wistuba, Ignacio I. (The University of Texas. Department of Translational Molecular Pathology) ;
Romero, Atocha (Hospital Universitario Puerta de Hierro Majadahonda (Madrid)) ;
Calvo, Virginia (Hospital Universitario Puerta de Hierro Majadahonda (Madrid)) ;
Provencio, Mariano (Hospital Universitario Puerta de Hierro Majadahonda (Madrid))
Purpose: Characterization of the T-cell receptor (TCR) repertoire may be a promising source for predictive biomarkers of pathologic response to immunotherapy in locally advanced non-small cell lung cancer (NSCLC). [...]
2021 - 10.1158/1078-0432.CCR-21-1200
Clinical Cancer Research, Vol. 27 Núm. 21 (November 2021) , p. 5878-5890
|
|
|
7.
|
|
19 p, 9.6 MB |
Gasdermin B over-expression modulates HER2-targeted therapy resistance by inducing protective autophagy through Rab7 activation
/
Gámez-Chiachio, Manuel (Centro de Investigación Biomédica en Red de Cáncer) ;
Molina-Crespo, Ángela (Universidad Autónoma de Madrid. Instituto de Investigaciones Biomédicas "Alberto Sols") ;
Ramos-Nebot, Carmen (Centro de Investigación Biomédica en Red de Cáncer) ;
Martinez-Val, Jeannette (Universidade de Santiago de Compostela) ;
Martinez, Lidia (Universidad Autónoma de Madrid) ;
Gassner, Katja (Mecanismos Moleculares Y Terapia Experimental en Oncologia-Programa OncobellIdibell (L'Hospitalet de Llobregat)) ;
Llobet, Francisco J. (Mecanismos Moleculares Y Terapia Experimental en Oncologia-Programa OncobellIdibell (L'Hospitalet de Llobregat)) ;
Soriano, Mario (Centro de Investigación Príncipe Felipe (València)) ;
Hernandez, Alberto (Centro de Investigación Príncipe Felipe (València)) ;
Cordani, Marco (Universidad Autónoma de Madrid) ;
Bernadó Morales, Cristina (Vall d'Hebron Institut d'Oncologia) ;
Diaz, Eva (Fundación MD Anderson Internacional (Madrid)) ;
Rojo-Sebastian, Alejandro (Fundación MD Anderson Internacional (Madrid)) ;
Triviño, Juan Carlos (Sistemas Genómicos) ;
Sánchez-García, Laura (Mecanismos Moleculares Y Terapia Experimental en Oncologia-Programa OncobellIdibell (L'Hospitalet de Llobregat)) ;
Rodríguez-Barrueco, Ruth (Universitat de Barcelona. Unitat d'Anatomia Humana i Embriologia) ;
Arribas, Joaquín V (Vall d'Hebron Institut d'Oncologia) ;
Llobet-Navás, David (Mecanismos Moleculares Y Terapia Experimental en Oncologia-Programa OncobellIdibell (L'Hospitalet de Llobregat)) ;
Sarrió, David (Centro de Investigación Biomédica en Red de Cáncer) ;
Moreno-Bueno, Gema (Fundación MD Anderson Internacional (Madrid)) ;
Universitat Autònoma de Barcelona
Gasdermin B (GSDMB) over-expression promotes poor prognosis and aggressive behavior in HER2 breast cancer by increasing resistance to therapy. Decoding the molecular mechanism of GSDMB-mediated drug resistance is crucial to identify novel effective targeted treatments for HER2/GSDMB aggressive tumors. [...]
2022 - 10.1186/s13046-022-02497-w
Journal of Experimental & Clinical Cancer Research : CR, Vol. 41 (september 2022)
|
|
|
8.
|
|
|
9.
|
|
17 p, 11.1 MB |
CXCR4-targeted nanotoxins induce GSDME-dependent pyroptosis in head and neck squamous cell carcinoma
/
Rioja-Blanco, Elisa (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Arroyo-Solera, Irene (Institut d'Investigació Biomèdica Sant Pau) ;
Álamo, Patricia (Institut d'Investigació Biomèdica Sant Pau) ;
Casanova Rigat, Isolda (Institut d'Investigació Biomèdica Sant Pau) ;
Gallardo, Alberto (Institut d'Investigació Biomèdica Sant Pau) ;
Unzueta Elorza, Ugutz (Institut d'Investigació Biomèdica Sant Pau) ;
Serna, Naroa (Universitat Autònoma de Barcelona. Institut de Biotecnologia i de Biomedicina "Vicent Villar Palasí") ;
Sánchez-García, Laura (Universitat Autònoma de Barcelona. Departament de Genètica i de Microbiologia) ;
Quer, Miquel (Institut d'Investigació Biomèdica Sant Pau) ;
Villaverde Corrales, Antonio (Universitat Autònoma de Barcelona. Institut de Biotecnologia i de Biomedicina "Vicent Villar Palasí") ;
Vázquez Gómez, Esther (Universitat Autònoma de Barcelona. Institut de Biotecnologia i de Biomedicina "Vicent Villar Palasí") ;
León i Vintró, Xavier (Institut d'Investigació Biomèdica Sant Pau) ;
Alba-Castellón, Lorena (Institut d'Investigació Biomèdica Sant Pau) ;
Mangues, Ramon 1957- (Institut d'Investigació Biomèdica Sant Pau)
Therapy resistance, which leads to the development of loco-regional relapses and distant metastases after treatment, constitutes one of the major problems that head and neck squamous cell carcinoma (HNSCC) patients currently face. [...]
2022 - 10.1186/s13046-022-02267-8
Journal of Experimental & Clinical Cancer Research : CR, Vol. 41 (february 2022)
|
|
|
10.
|
|
13 p, 2.4 MB |
Alternative splicing of human telomerase reverse transcriptase in gliomas and its modulation mediated by CX-5461
/
Li, Guihong (Zhengzhou, 450000 China) ;
Shen, Jing (Department of Cardiology, Shengze Hospital of Jiangsu Province, Suzhou, 215200 China) ;
Cao, Junguo (Changchun, 130021 China) ;
Zhou, Guangtong (Zhengzhou, 450000 China) ;
Lei, Ting (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Sun, Yuxue (Changchun, 130021 China) ;
Gao, Haijun (Changchun, 130021 China) ;
Ding, Yaonan (Changchun, 130021 China) ;
Xu, Weidong (Changchun, 130021 China) ;
Zhan, Zhixin (Changchun, 130021 China) ;
Chen, Yong (Changchun, 130021 China) ;
Huang, Haiyan (Changchun, 130021 China) ;
Universitat Autònoma de Barcelona
Glioma is a heterogeneous, invasive primary brain tumor with a wide range of patient survival and a lack of reliable prognostic biomarkers. Human telomerase reverse transcriptase (hTERT) has been reported in the presence of multiple transcripts in various tumor systems. [...]
2018 - 10.1186/s13046-018-0749-8
Journal of Experimental & Clinical Cancer Research : CR, Vol. 37 (april 2018)
|
|
visitante ::
identificación
alerta personal vía correo electrónico o subscríbase al 
canal RSS.
